Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.66 |
| ▸ | CTSD | P07339 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6329484 | 0.89 | CTSD (0.72) | MEN1KMT2ACTNNB1CTSDL3MBTL1 | |
| SCHEMBL7596694 | 0.87 | MEN1 (0.57) | MEN1KMT2ACTNNB1CTSDL3MBTL1 | |
| SCHEMBL974852 | 0.84 | CTNNB1 (0.62) | MEN1KMT2ACTNNB1L3MBTL1NPSR1 | |
| SCHEMBL22441045 | 0.82 | MEN1 (0.52) | MEN1KMT2ACTNNB1CTSDL3MBTL1 | |
| SCHEMBL5217469 | 0.82 | ALDH1A1 (0.50) | MEN1KMT2ACTNNB1CTSDL3MBTL1 | |
| SCHEMBL27674044 | 0.82 | CTNNB1 (0.61) | MEN1KMT2ACTNNB1L3MBTL1NPSR1 | |
| SCHEMBL6846935 | 0.82 | RAB9A (0.63) | MEN1KMT2ACTNNB1L3MBTL1NPSR1 | |
| SCHEMBL13883723 | 0.81 | L3MBTL1 (0.62) | MEN1KMT2ACTNNB1L3MBTL1NPSR1 | |
| SCHEMBL4180616 | 0.81 | L3MBTL1 (0.65) | MEN1KMT2ACTNNB1L3MBTL1NPSR1 | |
| SCHEMBL22319401 | 0.80 | L3MBTL1 (0.82) | KMT2AL3MBTL1NPSR1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319056-A1 | METHODS FOR TREATING CANCER | UNIV INDIANA TRUSTEES (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4144792-B1 | PARTICULATE WATER-ABSORBENT RESIN COMPOSITION, ABSORBENT BODY AND ABSORBENT ARTICLE | SUMITOMO SEIKA CHEMICALS (JP) | 2025-01-08 | — | — | EP | disclosed |
| EP-4144803-B1 | WATER ABSORBENT RESIN COMPOSITION, ABSORBENT, AND ABSORBENT ARTICLE | SUMITOMO SEIKA CHEMICALS (JP) | 2024-12-25 | — | — | EP | disclosed |
| CN-115516043-B | Particulate water-absorbent resin composition, absorber, and absorbent article | 住友精化株式会社 | 2024-06-28 | — | — | CN | disclosed |
| CN-115443312-B | Water-absorbent resin composition, absorber, and absorbent article | 住友精化株式会社 | 2024-05-14 | — | — | CN | disclosed |
| US-20230182112-A1 | PARTICULATE WATER-ABSORBING RESIN COMPOSITION, PRODUCTION METHOD THEREFOR, ABSORBENT OBJECT, AND ABSORBENT ARTICLE | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2023-06-15 | — | — | US | disclosed |
| US-20230165999-A1 | ABSORBENT ARTICLE | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2023-06-01 | — | — | US | disclosed |
| US-20230166238-A1 | PARTICULATE WATER-ABSORBENT RESIN COMPOSITION, ABSORBENT BODY AND ABSORBENT ARTICLE | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2023-06-01 | — | — | US | disclosed |
| US-20230166237-A1 | WATER ABSORBENT RESIN COMPOSITION, ABSORBENT, AND ABSORBENT ARTICLE | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2023-06-01 | — | — | US | disclosed |
| EP-4144790-A1 | PARTICULATE WATER-ABSORBING RESIN COMPOSITION, PRODUCTION METHOD THEREFOR, ABSORBENT OBJECT, AND ABSORBENT ARTICLE | Sumitomo Seika Chemicals Co., Ltd. (JP) | 2023-03-08 | — | — | EP | disclosed |
| EP-1392219-A2 | SUBSTITUTED N'-(ARYLCARBONYL)-BENZHYDRAZIDES, N'-(ARYLCARBONYL)-BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030149110-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | HU LAIN-YEN (US) | 2003-08-07 | — | — | US | disclosed |
| WO-2003045902-A1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER-LAMBERT COMPANY LLC (US) | 2003-06-05 | — | — | WO | disclosed |
| EP-1314723-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | WARNER-LAMBERT COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030013743-A1 | Substituted N'-(arylcarbonyl)-benzhydrazides, N'-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-01-16 | — | — | US | disclosed |
| WO-2002089745-A2 | SUBSTITUTED N'-(ARYLCARBONYL)-BENZHYDRAZIDES, N'-(ARYLCARBONYL)-BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-11-14 | — | — | WO | disclosed |
| US-5023334-A | Anthelmintic pyridinyl acylhydrazones | THE UPJOHN COMPANY (US) | 1991-06-11 | — | — | US | disclosed |
| US-5011932-A | Anthelmintic pyridinyl acylhydrazones derivatives | UPJOHN COMPANY (US) | 1991-04-30 | — | — | US | disclosed |
| EP-0214158-A1 | ANTHELMINTIC PYRIDINYL ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS | THE UPJOHN COMPANY (US) | 1987-03-18 | — | — | EP | disclosed |
| WO-1986004582-A1 | ANTHELMINTIC PYRIDINYL ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS | THE UPJOHN COMPANY (US) | 1986-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149110-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | BCAT1, BCAT2, ABAT | MEN1 2643/4885KMT2A 646/4885CTNNB1 951/4885 |
| US-20250319056-A1 | METHODS FOR TREATING CANCER | HSP90AB1, HSP90B1, HSP90AB2P | MEN1 3973/4885KMT2A 3452/4885CTNNB1 3412/4885 |
| US-20030013743-A1 | Substituted N'-(arylcarbonyl)-benzhydrazides, N'-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP2, CASP1, BCL2 | MEN1 2707/4885KMT2A 2862/4885CTNNB1 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.